八上英语语法总结 这个句子里面的ages是什么用法？Sinopharm'sCOVID-19 vaccine

来源：蜘蛛抓取(WebSpider) 时间：2023-11-21 06:00 标签： 八上英语语法总结

A man receives a dose of the Sinopharm coronavirus disease (COVID-19) vaccine, in Budapest, Hungary on February 26, 2021. [Photo/Agencies]
Early research shows that the inactivated COVID-19 vaccines produced by Sinopharm can provide protection against 10 mutated variants of SARS-CoV-2, including strains from the United Kingdom and South Africa, said Yu Qingming, Sinopharm's board chairman and a deputy to the National People's Congress.Many employees of the company received the vaccines last March, and after a year of monitoring, their antibody level still remained relatively high, Yu told People's Daily on Thursday.On Feb 25, the inactivated vaccine made by the Wuhan Institute of Biological Products, a Sinopharm affiliate, was granted conditional market approval. It is Sinopharm's second inactivated vaccine to be approved for market use, after the one developed by its subsidiary in Beijing."Over 5,000 deputies and members at this year's two sessions have been inoculated with Sinopharm's vaccines. This goes to show the strong trust people have in our vaccines," he said.However, Yu stressed that as COVID-19 vaccines are a relatively new product, scientists still need more research to definitively determine their efficacy. An inactivated vaccine is an established technique that uses dead viruses to induce an immune response. Some notable examples include the polio, whooping cough, rabies and hepatitis A virus vaccines.Based on interim analysis of data from phase-3 clinical trials, the United Arab Emirates Ministry of Health and Prevention said in December that Sinopharm's Beijing-developed vaccine offers an 86 percent protection rate against COVID-19. It also has 100 percent effectiveness in preventing moderate and severe cases of the disease.Recent experiments show that Sinopharm's vaccine can provide "broad spectrum protection" against mutated strains of COVID-19 viruses, "and can effectively protect against these new variants", said Yu.The vaccine made by the company's Wuhan affiliate is approved for the inoculation of people age 18 and older, which can include the elderly, Yu said. As for people ages 3 to 17, results from phase-3 trials show the vaccine to be safe and effective, although the findings must be evaluated by the National Medical Products Administration before the vaccine can be given to this age group, he added."As of now, 40 countries and regions have approved our vaccines for emergency use. We have also provided nearly 100 million doses to other countries, 60 million of which have been used without any serious adverse effects related to the vaccine."Sinopharm vaccines have been approved for market use in the UAE, Bahrain, China, Bolivia and Seychelles, Yu said.The company is continuing to ramp up its vaccine production and should reach an annual production capacity of over 3 billion doses. "It is currently the world's biggest COVID-19 vaccine manufacturer," he said.

Xinhua
Updated: 2021-05-12 15:06
Share
Share - WeChat
A healthcare worker in North Macedonia handles China's Sinopharm coronavirus disease (COVID-19) vaccines at a sport centre, as the country continues its mass inoculation campaign, in Stip, North Macedonia May 6, 2021. [Photo/Agencies]
GENEVA - China's Sinopharm COVID-19 vaccines, very much used globally, have been considered both safe and efficacious, according to Mariangela Simao, World Health Organization (WHO) assistant director general for access to health products."We still have data proving that they are efficacious against severe disease," she said in a press conference on Monday. "Sinopharm has been very much used globally. I think 62 million doses have already been applied. It has been considered both safe and efficacious."WHO Director-General Tedros Adhanom Ghebreyesus announced last week that China's Sinopharm COVID-19 vaccine has been validated for emergency use, marking the first Chinese vaccine officially recognized by the WHO.The approval came after an extensive review by an external, technical advisor group that looked at different data, Simao added."We did site inspections in China in January and February... We accessed the clinical data available for Sinopharm. It was also considered suitable, and (with) efficacy and safety in good manufacturing practice," she noted.She also mentioned that the WHO is committed to the COVAX Facility, which is "an equitable access mechanism that we are very much working on and striving to get enough doses to be distributed".The official called for a change in the code of behavior, as many vaccine producers "are moving towards a profit-driven approach instead of an equitable-access approach"."So (the) WHO is pushing very hard at the highest level for everyone who is manufacturing vaccines to consider putting those vaccines in a global mechanism that will ensure that all countries have access to them, not only high-income countries who can pay more for the vaccines, as we are seeing as we speak right now," Simao said."The code of behavior, when you talk about it, is not for vaccine nationalism. It is for everyone who has a product that can be a public health good and can help us in this acute phase of this pandemic," she stressed.

我要回帖

更多关于 八上英语语法总结 的文章

 

随机推荐